Impella RP Flex with SmartAssist intracardiac microaxial blood pump, Product Number 1000323
- Company
- Abiomed, Inc.
- Recall Initiated
- June 29, 2023
- Posted
- August 3, 2023
- Recall Number
- Z-2281-2023
- Quantity
- 166 units
- Firm Location
- Danvers, MA
Reason for Recall
A higher than expected rate of thrombus formation or deposition has been observed. The risk is for thrombus formations or deposits on indwelling central venous lines or cannulas may break free and enter into the Impella RP Flex, resulting in reduced flow, loss of support, or hemolysis
Distribution
US Nationwide distribution including in the states of AR, CA, FL, GA, LA, MA, MI, MO, NC, NJ, NY, OH, OR, SC, TX, and WI.
Lot / Code Info
UDI-DI: 00813502012811; Serial Numbers: 409541 409542 409544 411379 416645 416646 416647 416649 418933 418939 418940 419489 421953 421955 422974 422978 423999 425596 428726 428730 429616 429617 429623 429646 429648 429649 429650 429651 429652 429654 430363 430365 430366 430367 430923 430929 430931 431099 431106 431532 431535 431844 431846 431847 431848 431850 431868 431869 431870 432394 432395 432396 432397 432398 432400 432401 432402 432643 432644 432645 432648 432651 433755 433756 434540
Root Cause
Under Investigation by firm
Action Taken
An URGENT: MEDICAL DEVICE CORRECTION (NOTIFICATION) letter dated 6/29/23 was sent to customers. RECOMMENDATIONS: To minimize risk of thrombus formation or deposition, the following is recommended: " Maintenance of systemic anticoagulation (ACTs of 160-180 seconds) in particular when indwelling central venous lines (i.e., hemodialysis, PA catheters) are present, for the duration of Impella RP Flex with SmartAssist support as clinically feasible. " Assess the risk for extraluminal thrombus on indwelling lines (i.e., hemodialysis catheters, PA catheters) placed prior to initiation of support. " Users are reminded of the recommendations included in the best practices pathway on Figure 5.2 of IFU for optimal patient selection. In particular, elements that relate to the risk factors identified above: o Evidence of end-organ failure (bilirubin >5 or creatinine >4 within 24 hrs of implant) o Active infection (two of the following three: White Blood Cell (WBC) count >12,500, positive blood culture or fever) o Documented Deep Vein Thrombosis (DVT) o Patients on right-sided support or Extracorporeal Membrane Oxygenation (ECMO) Abiomed is revising the IFUs for the Impella RP Flex with SmartAssist to clarify the risk factors and recommendations related to the potential of thrombus formation or deposition. ACTIONS TO BE TAKEN BY CUSTOMER/USER " Product is NOT being removed from the field and does not need to be returned. " Review, complete all fields, sign, and return the attached business response form (BRF) on the last page of this letter to the Recall Coordinator identified in this document. Forward this notice to anyone in your facility that needs to be informed (i.e., those who manage, transport, store, stock, or use the subject products). " If any of the subject products have been forwarded to another facility, contact that facility and provide them with this notice. " Post a copy of this notice in a visible area for awareness of this field safety notice. " Follow th